Fate Therapeutics
FATE Small CapHealthcare · Biotechnology
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated i
Fate Therapeutics Stock at a Glance
Fate Therapeutics (FATE) is currently trading at $2.99 with a market capitalization of $348.5M. The 52-week range spans from $0.91 to $3.21; the current price is 6.9% below the yearly high. Year-over-year revenue growth stands at -20.3%.
💰 Dividend
Fate Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
9 analysts rate Fate Therapeutics (FATE) on consensus: Buy. The average price target is $5.41, implying +80.97% from the current price. Analyst price targets range from $2.20 to $8.00.
Fate Therapeutics: The Investment Case in Detail
Fate Therapeutics (FATE) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Wall Street consensus sits at Buy with an average price target implying roughly 80.97% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Revenue is contracting at -20.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a beta near 2.52, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 10.52% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
What to Watch Next
- The share is trading at 90.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
- The analyst consensus price target implies 80.97% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 42.73)
- –Revenue shrinking (-20.3% YoY)
- –High volatility (Beta 2.52)
- –High short interest (10.52%)
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (10.52%).
Trading Data
Related Stocks in the Same Sector
Fate Therapeutics at 1.75 dollars: iPSC-derived NK and T-cell immunotherapy pioneer near cash-floor
The Real Story
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies derived from induced pluripotent stem cells (iPSC) — engineered NK cells and T cells designed as off-the-shelf alternatives to autologous CAR-T therapies like Kymriah and Yescarta. The leading candidates include FT522 (CAR-NK for B-cell lymphoma and autoimmunity) and FT836 (CAR-T for tumors). The iPSC platform theoretically allows allogeneic (donor-independent) treatment at a fraction of CAR-T costs.
The market hates this stock because Fate's 2023 collaboration with Janssen (Johnson and Johnson) was terminated, the FT-538 program was paused, and the company has restructured twice. Trailing EPS minus 1.09, P/B 1.14, market cap 204 million USD. The market has effectively priced the equity as cash-floor — meaning if the company runs out of cash without a partner, equity goes to zero.
What Smart Money Thinks
Founder and former CEO Scott Wolchko stepped down in 2024. RA Capital Management (life-sciences fund) had a position. Insider activity has been minimal in recent years.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
📉 The 3 Real Bear Points
Valuation in Context
Standard valuation does not apply. Negative earnings, EV/Sales 16.9 on tiny revenue, market cap roughly equals cash. The stock is an option: if any of the three programs reads out positively in 2026, multi-bagger; if cash runs out before readout, equity wipeout via dilutive financing.
🗓️ Next 3 Catalyst Dates
- :
- :
- :
💬 Daniel's Take
FATE is a clinical-stage biotech option with a cash-floor characteristic. I only want exposure to high-risk biotech through a diversified basket of 15 to 20 names; FATE belongs in that basket as a 0.2 to 0.4 percent position. The autoimmunity angle is the interesting wildcard — if iPSC-derived NK cells work in autoimmunity, the market is multiples of oncology. Risk is cash runs out before readout; reward is takeout or multi-bagger.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Fate Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news